Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vivozon Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals sector. These actions are split between 2 distinct examiners and 2 distinct art units. BRUCK KIFLE is the busiest examiner with 1 pending action. This distribution of actions to examiners and art units indicates a dispersed prosecution footprint.
The presence of 2 distinct art units for the pending actions suggests that each matter falls into a different specialized category within Biotechnology & Pharmaceuticals. With 2 examiners involved, the company is receiving feedback from multiple perspectives. BRUCK KIFLE's assignment of 1 pending action highlights the nature of their current legal challenges. The 2 pending actions represent the current extent of the company's USPTO activity, ensuring that each application is evaluated on its own technical merits.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729378 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | KIFLE, BRUCK | — |
| 17596397 | METHOD OF PREVENTING OR TREATING POSTOPERATIVE PAIN | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729378 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | KIFLE, BRUCK | 1624 | §112Other | Non-Final OA | — | Pending | Jan 03, 2025 |
| 17596397 | METHOD OF PREVENTING OR TREATING POSTOPERATIVE PAIN | PECKHAM, RICHARD GRANT | 1627 | §103DP | Non-Final OA | — | Pending | Dec 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVivozon Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bruck Kifle has the most, with 1 of Vivozon Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
